Universitätsmedizin Mannheim
Universitätsmedizin Mannheim
Mannheim, Germany8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT06832722 | |
| Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection | VEXAS syndrome | Recruiting | Not stated | 2026-05-15 | NCT06377462 | |
| TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma | Esophagogastric Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-04-02 | NCT07507968 | |
| Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, intrahepatic cholangiocarcinoma, neoplasm | Active, not recruiting | Phase 2 | 2025-12-05 | NCT05174650 | |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication | Recruiting | Phase 2 | 2024-12-27 | NCT05762211 | |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | Active, not recruiting | Phase 3 | 2024-10-17 | NCT04769895 | |
| The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Enrolling by invitation | Not stated | 2023-03-14 | NCT05677568 | |
| Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes | Cytopenia, Hemic and Lymphatic Diseases, blood platelet disease, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, thrombocytopenia | Active, not recruiting | Phase 2 | 2022-01-28 | NCT02912208 |